IJDVL Home  
 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]  
Year : 2005  |  Volume : 71  |  Issue : 6  |  Page : 398-400

Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study

Kanu Mangla, Swati Rastogi, Puneet Goyal, Rekha B Solanki, Ranjan C Rawal 
 Department of Dermatology, V. S. Hospital, Ahmedabad, India

Correspondence Address:
Ranjan C Rawal
Department of Dermatology, V. S. Hospital, Ahmedabad
India

Background: High dose intravenous immunoglobulins (IVIG) have emerged as a promising new therapy for treating the rare but potentially fatal drug reaction toxic epidermal necrolysis (TEN). Experimental in vitro studies support the view that IVIG can block the fas-fas ligand mediated apoptosis in TEN. Methods: Ten pediatric patients of TEN were treated with IVIG (0.05 - 0.1 gm/kg/day) along with antibiotics and supportive care. Results: Patients with 67% of mean body surface area of involvement showed an average of 2.1 days for arrest of progression of lesions and 8.1 days for complete reepithelization. There was no mortality. Conclusions: Low dose IVIG appears to be a safe and effective treatment for TEN in children. Randomized trials are needed to further evaluate the efficacy of IVIG and compare it with other therapeutic modalities.


How to cite this article:
Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study.Indian J Dermatol Venereol Leprol 2005;71:398-400


How to cite this URL:
Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study. Indian J Dermatol Venereol Leprol [serial online] 2005 [cited 2020 Jul 8 ];71:398-400
Available from: http://www.ijdvl.com/article.asp?issn=0378-6323;year=2005;volume=71;issue=6;spage=398;epage=400;aulast=Mangla;type=0


 

Wednesday, July 8, 2020
 Site Map | Home | Contact Us | Feedback | Copyright and disclaimer